Correction: Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade.

Authors:
NA

Journal:
J Immunother Cancer

Publication Year: 2024

DOI:
10.1136/jitc-2022-004762corr1

PMCID:
PMC10828831

PMID:
38290771

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Immunother Cancer

Abbreviation: J Immunother Cancer

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Therapeutics

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentic…
Ma C; Chen P; Du J and 7 more (2024) - Transparency Score: 5/6
An oncolytic vaccinia virus encoding hyaluronidase reshapes the extracellular matrix to enhance can…
Wang S; Li Y; Xu C and 2 more (2024) - Transparency Score: 3/6
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK …
Desroys du Roure P; Lajoie L; Mallavialle A and 19 more (2024) - Transparency Score: 4/6
Associations of concomitant medications with immune-related adverse events and survival in advanced…
Nara K; Taguchi S; Buti S and 5 more (2024) - Transparency Score: 4/6
Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase …
Huffman BM; Singh H; Ali LR and 35 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
1/6
16.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025